2'-Fluorinated Nucleoside Chemistry for New Drug Discovery: Achievements and Prospects

Overview

Journal Natl Sci Rev

Date 2024 Nov 11

PMID 39526027

Authors

Yonggang Meng

Nannan Sun

Lan Liang

Bin Yu

Junbiao Chang

Affiliations

Soon will be listed here.

Abstract

Fluorinated nucleosides are an important class of modified nucleosides that have demonstrated therapeutic potential for treating various human diseases, especially viral infections and cancer. Many fluorinated nucleosides have advanced into clinical trials or have been approved by the FDA for use in patients. Among these fluorinated nucleosides, azvudine, developed by us, has been officially approved by the National Medical Products Administration for the treatment of coronavirus disease 2019 (COVID-19) and human immunodeficiency virus, indicating the therapeutic promise of fluorinated nucleosides. In view of the therapeutic promise of fluorinated nucleosides for antiviral and anticancer therapy, in this Review we will provide a comprehensive overview of well-established 2'-fluorinated nucleosides approved for use in the market or those in clinical stages for antiviral and antitumor therapies, highlighting the drug discovery strategies, structure-activity relationship studies, mechanisms of action, and preclinical/clinical studies and also discuss the challenges and future directions for nucleoside-based new drug discovery.

Citing Articles

Molecular evolution of nucleoside deoxyribosyl transferase to enhance the activity toward 2'-fluoro-2'-deoxynucleoside.

Yang S, Yoo Y, Choi K, Kim B, Choi S, Kang S J Ind Microbiol Biotechnol. 2025; 52.

PMID: 39999854 PMC: 11892431. DOI: 10.1093/jimb/kuaf005.

RNA Stability: A Review of the Role of Structural Features and Environmental Conditions.

Kornienko I, Aramova O, Tishchenko A, Rudoy D, Chikindas M Molecules. 2025; 29(24.

PMID: 39770066 PMC: 11676819. DOI: 10.3390/molecules29245978.

References

Venugopal B, Awada A, Evans T, Dueland S, Hendlisz A, Rasch W . A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours. Cancer Chemother Pharmacol. 2015; 76(4):785-92. DOI: 10.1007/s00280-015-2846-0. View

Calabresi P, McCOLLUM R, WELCH A . Suppression of infections resulting from a deoxyribonucleic acid virus (vaccinia) by systemic adminstration of 5-iodo-2'-deoxyuridine. Nature. 1963; 197:767-9. DOI: 10.1038/197767a0. View

Reddy P, Bao D, Chang W, Chun B, Du J, Nagarathnam D . 2'-deoxy-2'-α-fluoro-2'-β-C-methyl 3',5'-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: discovery of PSI-352938. Bioorg Med Chem Lett. 2010; 20(24):7376-80. DOI: 10.1016/j.bmcl.2010.10.035. View

Sun J, Yogarajah T, Lee R, Kaur P, Inoue M, Tan Y . Drug repurposing of pyrimidine analogs as potent antiviral compounds against human enterovirus A71 infection with potential clinical applications. Sci Rep. 2020; 10(1):8159. PMC: 7235037. DOI: 10.1038/s41598-020-65152-4. View

Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G . Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003; 102(7):2379-86. DOI: 10.1182/blood-2003-03-0925. View

Guo X, Li Y, Tao L, Wang Q, Wang S, Hu W . Synthesis and anti-HIV-1 activity of 4-substituted-7-(2'-deoxy-2'-fluoro-4'-azido-β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine analogues. Bioorg Med Chem Lett. 2011; 21(22):6770-2. DOI: 10.1016/j.bmcl.2011.09.040. View

Brox L, LePAGE G, Hendler S, Shannahoff D . Studies on the growth inhibition and metabolism of 2'-deoxy-2'-fluorocytidine in cultured human lymphoblasts. Cancer Res. 1974; 34(8):1838-42. View

Tsesmetzis N, Paulin C, Rudd S, Herold N . Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism. Cancers (Basel). 2018; 10(7). PMC: 6071274. DOI: 10.3390/cancers10070240. View

Huang P, Chubb S, Hertel L, GRINDEY G, Plunkett W . Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991; 51(22):6110-7. View

10.

McKenzie R, Fried M, Sallie R, Conjeevaram H, Di Bisceglie A, Park Y . Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 1995; 333(17):1099-105. DOI: 10.1056/NEJM199510263331702. View

11.

Koff R . Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2014; 39(5):478-87. DOI: 10.1111/apt.12601. View

12.

Schinazi R, Fox J, WATANABE K, Nahmias A . Activities of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine and its metabolites against herpes simplex virus types 1 and 2 in cell culture and in mice infected intracerebrally with herpes simplex virus type 2. Antimicrob Agents Chemother. 1986; 29(1):77-84. PMC: 180368. DOI: 10.1128/AAC.29.1.77. View

13.

Rodriguez-Torres M . Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection. Expert Rev Anti Infect Ther. 2013; 11(12):1269-79. DOI: 10.1586/14787210.2013.855126. View

14.

Niu C, Tolstykh T, Bao H, Park Y, Babusis D, Lam A . Metabolic activation of the anti-hepatitis C virus nucleotide prodrug PSI-352938. Antimicrob Agents Chemother. 2012; 56(7):3767-75. PMC: 3393470. DOI: 10.1128/AAC.00530-12. View

15.

Infante J, Benhadji K, Dy G, Fetterly G, Ma W, Bendell J . Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumors. Invest New Drugs. 2015; 33(2):432-9. DOI: 10.1007/s10637-015-0207-9. View

16.

Liu S, Grove K, Cheng Y . Unique metabolism of a novel antiviral L-nucleoside analog, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase. Antimicrob Agents Chemother. 1998; 42(4):833-9. PMC: 105551. DOI: 10.1128/AAC.42.4.833. View

17.

Staschke K, Colacino J, Mabry T, Jones C . The in vitro anti-hepatitis B virus activity of FIAU [1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl-5-iodo)uracil] is selective, reversible, and determined, at least in part, by the host cell. Antiviral Res. 1994; 23(1):45-61. DOI: 10.1016/0166-3542(94)90032-9. View

18.

Asif G, Hurwitz S, Shi J, Hernandez-Santiago B, Schinazi R . Pharmacokinetics of the antiviral agent beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine in rhesus monkeys. Antimicrob Agents Chemother. 2007; 51(8):2877-82. PMC: 1932527. DOI: 10.1128/AAC.00193-07. View

19.

Pierra Rouviere C, Dousson C, Tavis J . HBV replication inhibitors. Antiviral Res. 2020; 179:104815. PMC: 7293572. DOI: 10.1016/j.antiviral.2020.104815. View

20.

Zhang Y, Zhang R, Ding X, Peng B, Wang N, Ma F . FNC efficiently inhibits mantle cell lymphoma growth. PLoS One. 2017; 12(3):e0174112. PMC: 5363836. DOI: 10.1371/journal.pone.0174112. View